| Leukemia, Myelocytic, Acute
Rydapt vs Vanflyta
Side-by-side clinical, coverage, and cost comparison for leukemia, myelocytic, acute.Deep comparison between: Rydapt vs Vanflyta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVanflyta has a higher rate of injection site reactions vs Rydapt based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vanflyta but not Rydapt, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rydapt
Vanflyta
At A Glance
Oral
Twice daily
Multi-kinase inhibitor
Oral
Once daily
FLT3 inhibitor
Indications
- Leukemia, Myelocytic, Acute
- Aggressive Systemic Mastocytosis
- Systemic mastocytosis with associated clonal, hematologic non-mast-cell lineage disease
- Leukemia, Mast-Cell
- Leukemia, Myelocytic, Acute
Dosing
Leukemia, Myelocytic, Acute 50 mg orally twice daily with food on Days 8 to 21 of each induction cycle with cytarabine and daunorubicin and on Days 8 to 21 of each consolidation cycle with high-dose cytarabine.
Aggressive Systemic Mastocytosis, Systemic mastocytosis with associated clonal, hematologic non-mast-cell lineage disease, Leukemia, Mast-Cell 100 mg orally twice daily with food; continue until disease progression or unacceptable toxicity.
Leukemia, Myelocytic, Acute Induction: 35.4 mg orally once daily on Days 8 to 21 of each 28-day cycle, up to 2 cycles with cytarabine and anthracycline; Consolidation: 35.4 mg once daily on Days 6 to 19 of each cycle, up to 4 cycles with high-dose cytarabine; Maintenance: 26.5 mg once daily (escalate to 53 mg on Day 15 if QTcF <=450 ms), continuous once-daily with no break for up to 36 cycles.
Contraindications
- Hypersensitivity to midostaurin or any excipient, including reactions such as anaphylactic shock, dyspnea, flushing, chest pain, and angioedema
- Severe hypokalemia
- Severe hypomagnesemia
- Long QT syndrome
- History of ventricular arrhythmias or torsades de pointes
Adverse Reactions
Most common (>=20%) - AML Febrile neutropenia, nausea, mucositis, vomiting, headache, petechiae, musculoskeletal pain, epistaxis, device-related infection, hyperglycemia, ECG QT prolonged, upper respiratory tract infections
Most common (>=20%) - Systemic Mastocytosis Nausea, vomiting, diarrhea, edema, musculoskeletal pain, abdominal pain, fatigue, upper respiratory tract infection, constipation, pyrexia, headache, dyspnea
Serious Pulmonary toxicity, febrile neutropenia, sepsis, gastrointestinal hemorrhage, pneumonia, cardiac events
Postmarketing Interstitial lung disease, acute febrile neutrophilic dermatosis (Sweet syndrome)
Most common (>=10%) Febrile neutropenia, diarrhea, mucositis, nausea, sepsis, abdominal pain, vomiting, neutropenia, headache, upper respiratory tract infection, hypertransaminasemia, thrombocytopenia, fungal infection, herpesvirus infection, decreased appetite, epistaxis, insomnia, electrocardiogram QT prolonged, anemia, dyspepsia, eye irritation.
Serious Febrile neutropenia, sepsis, fungal infections, brain edema, pneumonia, cerebral infarction, acute respiratory distress syndrome, pulmonary embolism, ventricular dysfunction, cardiac arrest.
Pharmacology
Midostaurin is a multi-kinase inhibitor that inhibits wild type and mutant FLT3, KIT (wild type and D816V), PDGFRalpha/beta, and members of the PKC serine/threonine kinase family, inducing apoptosis in leukemic cells expressing FLT3 mutations and inhibiting KIT signaling and histamine release in mast cells.
Quizartinib is a small molecule inhibitor of the receptor tyrosine kinase FLT3; it and its active metabolite AC886 bind the ATP binding domain of FLT3, inhibiting kinase activity and downstream FLT3 receptor signaling, thereby blocking FLT3-ITD-dependent cell proliferation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Rydapt.
Vanflyta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
No coverage data available for Rydapt.
Vanflyta
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
No coverage data available for Rydapt.
Vanflyta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/momo
Novartis Oncology Universal Co-pay Program: RydaptCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RydaptView full Rydapt profile
VanflytaView full Vanflyta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.